271 related articles for article (PubMed ID: 16396063)
1. Sustained virological response rate to pegylated interferon plus ribavirin for chronic hepatitis C in African Americans: results in treatment-naïve patients in a university liver clinic.
Srivastava S; Bertagnolli M; Lewis JH
J Natl Med Assoc; 2005 Dec; 97(12):1703-7. PubMed ID: 16396063
[TBL] [Abstract][Full Text] [Related]
2. Equally poor outcomes to pegylated interferon-based therapy in African Americans and Hispanics with chronic hepatitis C infection.
Satapathy SK; Lingisetty CS; Proper S; Chaudhari S; Williams S
J Clin Gastroenterol; 2010 Feb; 44(2):140-5. PubMed ID: 19826275
[TBL] [Abstract][Full Text] [Related]
3. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
Shepherd J; Brodin H; Cave C; Waugh N; Price A; Gabbay J
Health Technol Assess; 2004 Oct; 8(39):iii-iv, 1-125. PubMed ID: 15461877
[TBL] [Abstract][Full Text] [Related]
4. Treatment outcomes with pegylated interferon and ribavirin for male prisoners with chronic hepatitis C.
Chew KW; Allen SA; Taylor LE; Rich JD; Feller E
J Clin Gastroenterol; 2009 Aug; 43(7):686-91. PubMed ID: 19295448
[TBL] [Abstract][Full Text] [Related]
5. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.
Hartwell D; Jones J; Baxter L; Shepherd J
Health Technol Assess; 2011 Apr; 15(17):i-xii, 1-210. PubMed ID: 21473834
[TBL] [Abstract][Full Text] [Related]
6. Response to therapy with pegylated interferon and ribavirin for chronic hepatitis C in hispanics compared to non-Hispanic whites.
Yu S; Douglass JM; Qualls C; Arora S; Dunkelberg JC
Am J Gastroenterol; 2009 Jul; 104(7):1686-92. PubMed ID: 19436272
[TBL] [Abstract][Full Text] [Related]
7. Pegylated interferon alfa and ribavirin for children with chronic hepatitis C.
Rosen I; Kori M; Eshach Adiv O; Yerushalmi B; Zion N; Shaoul R
World J Gastroenterol; 2013 Feb; 19(7):1098-103. PubMed ID: 23467199
[TBL] [Abstract][Full Text] [Related]
8. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1.
Jeffers LJ; Cassidy W; Howell CD; Hu S; Reddy KR
Hepatology; 2004 Jun; 39(6):1702-8. PubMed ID: 15185312
[TBL] [Abstract][Full Text] [Related]
9. Early and sustained virological response in non-responders with chronic hepatitis C: a randomized open-label study of pegylated interferon-alpha-2a versus pegylated interferon-alpha-2b.
Scotto G; Fazio V; Fornabaio C; Tartaglia A; Di Tullio R; Saracino A; Angarano G
Drugs; 2008; 68(6):791-801. PubMed ID: 18416586
[TBL] [Abstract][Full Text] [Related]
10. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
[TBL] [Abstract][Full Text] [Related]
11. Optimum ribavirin exposure overcomes racial disparity in efficacy of peginterferon and ribavirin treatment for hepatitis C genotype 1.
Jin R; Cai L; Tan M; McHutchison JG; Dowling TC; Howell CD
Am J Gastroenterol; 2012 Nov; 107(11):1675-83. PubMed ID: 23090351
[TBL] [Abstract][Full Text] [Related]
12. Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C.
Ishiguro H; Abe H; Seki N; Sugita T; Aida Y; Itagaki M; Sutoh S; Shimada N; Furihata T; Tsubota A; Aizawa Y
World J Gastroenterol; 2015 Apr; 21(13):3904-11. PubMed ID: 25852275
[TBL] [Abstract][Full Text] [Related]
13. Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infection.
Rodriguez-Torres M; Lawitz E; Yangco B; Jeffers L; Han SH; Thuluvath PJ; Rustgi V; Harrison S; Ghalib R; Vierling JM; Luketic V; Zamor PJ; Ravendhran N; Morgan TR; Pearlman B; O'Brien C; Khallafi H; Pyrsopoulos N; Kong G; McPhee F; Yin PD; Hughes E; Treitel M
Ann Hepatol; 2016 Nov-Dec 2016; 15(6):834-845. PubMed ID: 27740516
[TBL] [Abstract][Full Text] [Related]
14. Prediction of sustained virological response to combination therapy with pegylated interferon alfa and ribavirin in patients with genotype 3 chronic hepatitis C.
Tohra SK; Taneja S; Ghosh S; Sharma BK; Duseja A; Dhiman RK; Das A; Chawla YK
Dig Dis Sci; 2011 Aug; 56(8):2449-55. PubMed ID: 21706207
[TBL] [Abstract][Full Text] [Related]
15. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.
Escudero A; Rodríguez F; Serra MA; Del Olmo JA; Montes F; Rodrigo JM
J Gastroenterol Hepatol; 2008 Jun; 23(6):861-6. PubMed ID: 18422960
[TBL] [Abstract][Full Text] [Related]
16. Associations between serum lipids and hepatitis C antiviral treatment efficacy.
Ramcharran D; Wahed AS; Conjeevaram HS; Evans RW; Wang T; Belle SH; Yee LJ;
Hepatology; 2010 Sep; 52(3):854-63. PubMed ID: 20690192
[TBL] [Abstract][Full Text] [Related]
17. Predictors of sustained virological response to a 48-week course of pegylated interferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4.
Al Ashgar H; Helmy A; Khan MQ; Al Kahtani K; Al Quaiz M; Rezeig M; Kagevi I; Alshehri A; Al Kalbani A; Al Swat K; Dahab S; Elkum N; Al Fadda M
Ann Saudi Med; 2009; 29(1):4-14. PubMed ID: 19139619
[TBL] [Abstract][Full Text] [Related]
18. Negative HCV-RNA 2 weeks after initiation of treatment predicts sustained virological response to pegylated interferon alfa-2a and ribavirin in patients with chronic hepatitis C.
Christensen PB; Krarup HB; Laursen AL; Madsen PH; Pedersen C; Schlichting P; Orholm M; Ring-Larsen H; Bukh J; Krogsgaard K
Scand J Gastroenterol; 2012 Sep; 47(8-9):1115-9. PubMed ID: 22670704
[TBL] [Abstract][Full Text] [Related]
19. Peginterferon alfa-2a and ribavirin for chronic hepatitis C genotype 1 infections in black patients: safety, tolerability and impact on sustained virologic response.
Howell CD; Jeffers LS; Cassidy W; Reddy KR; Hu S; Lee JS
J Viral Hepat; 2006 Jun; 13(6):371-6. PubMed ID: 16842439
[TBL] [Abstract][Full Text] [Related]
20. Vitamin D and the racial difference in the genotype 1 chronic hepatitis C treatment response.
Weintraub SJ; Fleckenstein JF; Marion TN; Madey MA; Mahmoudi TM; Schechtman KB
Am J Clin Nutr; 2012 Nov; 96(5):1025-31. PubMed ID: 23015322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
